Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 11433 - 11440 of 12008 results

FEDERAL COURT REJECTS BID TO SCRAP THE NLRB'S RULE REQUIRING NON-UNION EMPLOYERS TO POST NOTICE OF UNIONIZATION RIGHTS
March 8, 2012| Blog| Viewpoint

New York Court Finds Private Right of Action Under State’s Prompt Pay Law
March 8, 2012| Blog| Viewpoint

Consumer Privacy Bill of Rights - Summary and Invitation to Comment
March 7, 2012| Blog| Viewpoint

New FDA Research Consent Form Requirements – Effective Today
March 7, 2012| Blog| Viewpoint

ML Strategies Posts Weekly Health Care Reform Update on March 5, 2012
March 5, 2012| Blog| Viewpoint

ACGME Announces its Next Accreditation System
March 5, 2012| Blog| Viewpoint

CMS Issues Final Payment Error Calculation Methodology for Medicare Advantage RADV Audits
March 1, 2012| Blog| Viewpoint

Leave of Absence as Reasonable Accommodation for Disability? It Depends.
February 29, 2012| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
